Open AccessRecommendations for the management of COVID 19 patients regarding proarrhythmic effects of some current treatments, specifically if these patients suffer from arrhythmias, and for those receiving antiarrhythmic therapy.
Author(s) -
А. Ардашев,
Oscar Oseroff,
Rodolfo Sansalone,
E. Zhelyakov,
Riccardo Cappato,
V. A. Snezhitskiy,
С. Г. Канорский,
S. Abzalieva S. Abzalieva,
Yury Belenkov,
Yury Karpenko,
Aras Puodžiūkynas,
S. A. Sayganov,
Luca Santini,
Ricardo Speranza,
Marina Yakovleva,
Ludmila Kolotsey
Publication year - 2020
Publication title -
kardiologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.159
H-Index - 16
eISSN - 2412-5660
pISSN - 0022-9040
DOI - 10.18087/cardio.2020.10.n1283
Subject(s) - covid-19 , medicine , adverse effect , intensive care medicine , cardiology , anti arrhythmia agents , atrial fibrillation , disease , virology , outbreak , infectious disease (medical specialty)
Recommendation provides information to employees of medical departments at any level and primarily primary care about the possible proarrhythmic and adverse effects of drugs used for the treatment of COVID-19 patients and the features of therapy for COVID-19 patients with heart rhythm and conduction disorders receiving permanent antiarrhythmic therapy.